Replimune reels in $30 mln Series A

UK-based Replimune, a developer of oncolytic immunotherapy, has secured $30 million in Series A funding. Atlas Venture led the round with participation from return backers Forbion Capital Partners and Omega Funds. In addition to the funding, Jason Rhodes of Atlas, Otello Stampacchia of Omega and Sander Slootweg of Forbion have been added to Replimune's board.

North AmericaUSBriefs